M
Melyssa Aronson
Researcher at Mount Sinai Hospital, Toronto
Publications - 122
Citations - 6962
Melyssa Aronson is an academic researcher from Mount Sinai Hospital, Toronto. The author has contributed to research in topics: Lynch syndrome & Cancer. The author has an hindex of 32, co-authored 100 publications receiving 5889 citations. Previous affiliations of Melyssa Aronson include Hospital for Sick Children & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.
Robert Gryfe,Hyeja Kim,Eugene T.K. Hsieh,Melyssa Aronson,Eric J. Holowaty,Shelley B. Bull,Mark Redston,Steven Gallinger +7 more
TL;DR: High-frequency microsatellite instability in colorectal cancer is independently predictive of a relatively favorable outcome and, in addition, reduces the likelihood of metastases.
Journal ArticleDOI
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet,Valérie Larouche,Brittany Campbell,Daniele Merico,Richard de Borja,Melyssa Aronson,Carol Durno,Joerg Krueger,Vanja Cabric,Vijay Ramaswamy,Nataliya Zhukova,Gary Mason,Roula Farah,Samina Afzal,Michal Yalon,Gideon Rechavi,Vanan Magimairajan,Michael Walsh,Shlomi Constantini,Rina Dvir,Ronit Elhasid,Alyssa Reddy,Michael Osborn,Michael J. Sullivan,Jordan R. Hansford,Andrew Dodgshun,Nancy Klauber-DeMore,Lindsay L. Peterson,Sunil J. Patel,Scott Lindhorst,Jeffrey Atkinson,Zane Cohen,Rachel Laframboise,Peter B. Dirks,Michael D. Taylor,David Malkin,Steffen Albrecht,Roy W. R. Dudley,Nada Jabado,Cynthia Hawkins,Adam Shlien,Uri Tabori +41 more
TL;DR: This report of initial and durable responses of recurrent GBM to immune checkpoint inhibition may have implications for GBM in general and other hypermutant cancers arising from primary (genetic predisposition) or secondary MMRD.
Journal ArticleDOI
Comprehensive Analysis of Hypermutation in Human Cancer
Brittany Campbell,Nicholas Light,David Fabrizio,Matthew Zatzman,Fabio Fuligni,Richard de Borja,Scott Davidson,Melissa Edwards,Julia A. Elvin,Karl P. Hodel,Walter J. Zahurancik,Zucai Suo,Tatiana Lipman,Katharina Wimmer,Christian P. Kratz,Daniel C. Bowers,Theodore W. Laetsch,Gavin P. Dunn,Tanner M. Johanns,Matthew R. Grimmer,Ivan Smirnov,Valerie Larouche,David Samuel,Annika Bronsema,Michael Osborn,Duncan Stearns,Pichai Raman,Kristina A. Cole,Phillip B. Storm,Michal Yalon,Enrico Opocher,Gary Mason,Gregory Thomas,Magnus Sabel,Ben George,David S. Ziegler,David S. Ziegler,Scott Lindhorst,Vanan Magimairajan Issai,Shlomi Constantini,Helen Toledano,Ronit Elhasid,Roula Farah,Rina Dvir,Peter B. Dirks,Annie Huang,Melissa Galati,Jiil Chung,Vijay Ramaswamy,Meredith S. Irwin,Melyssa Aronson,Carol Durno,Michael D. Taylor,Gideon Rechavi,John M. Maris,Eric Bouffet,Cynthia Hawkins,Joseph F. Costello,M. Stephen Meyn,M. Stephen Meyn,Zachary F. Pursell,David Malkin,Uri Tabori,Adam Shlien +63 more
TL;DR: An extensive assessment of mutation burden through sequencing analysis of >81,000 tumors from pediatric and adult patients, including tumors with hypermutation caused by chemotherapy, carcinogens, or germline alterations, uncovered new driver mutations in the replication-repair-associated DNA polymerases and a distinct impact of microsatellite instability and replication repair deficiency on the scale of mutation load.
Journal ArticleDOI
Lower Cancer Incidence in Amsterdam-I Criteria Families Without Mismatch Repair Deficiency: Familial Colorectal Cancer Type X
Noralane M. Lindor,Kari G. Rabe,Gloria M. Petersen,Robert W. Haile,Graham Casey,John A. Baron,Steve Gallinger,Bharati Bapat,Melyssa Aronson,John L. Hopper,Jeremy R. Jass,Loic LeMarchand,John S. Grove,John D. Potter,Polly A. Newcomb,Jonathan P. Terdiman,Peggy Conrad,Gabriella Moslein,Richard M. Goldberg,Argyrios Ziogas,Hoda Anton-Culver,Mariza de Andrade,Kim Siegmund,Stephen N. Thibodeau,Lisa A. Boardman,Daniela Seminara +25 more
TL;DR: Families who fulfill AC-I criteria but who have no evidence of a DNA MMR defect do not share the same cancer incidence as families with HNPCC-Lynch syndrome, and the designation of "familial colorectal cancer type X" is suggested to describe this type of familial aggregation of coloreCTal cancer.
Journal ArticleDOI
Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers
Laura Baglietto,Noralane M. Lindor,James G. Dowty,Darren M. White,Anja Wagner,Encarna B. Gomez Garcia,Annette H. J. T. Vriends,Annette H. J. T. Vriends,Nicola Cartwright,Rebecca A. Barnetson,Susan M. Farrington,Albert Tenesa,Heather Hampel,Daniel D. Buchanan,Sven Arnold,Joanne P. Young,Michael Walsh,Jeremy R. Jass,Finlay A. Macrae,Yoland Antill,Ingrid Winship,Ingrid Winship,Graham G. Giles,Jack Goldblatt,Susan Parry,Graeme Suthers,Graeme Suthers,Barbara A. Leggett,Malinda L. Butz,Melyssa Aronson,Jenny N. Poynter,John A. Baron,Loic Le Marchand,Robert W. Haile,Steve Gallinger,John L. Hopper,John D. Potter,Albert de la Chapelle,Hans F. A. Vasen,Malcolm G. Dunlop,Stephen N. Thibodeau,Mark A. Jenkins +41 more
TL;DR: Estimates of both absolute and relative cancer risks for MSH6 mutation carriers are obtained, which are precise and accurate.